American experts have discovered that patients with severe and incurable arthritis benefit if they are given an anti-arthritic drug, as well as an anti-arthritis drug, Crestexa.
It should be noted that the increase in uric acid in the blood is due to arthritis, the most prominent effect of which is manifested in the form of stiffness, pain and swelling in the joints.
There are many medicines for arthritis, but for most patients a drug called ‘Krystexxa’ is prescribed which reduces the amount of uric acid in the blood and relaxes the patient. However, the response of the natural immune system to the disease affects the effectiveness of the drug and reduces it.
With this in mind, Dr. Pooja Khanna of the University of Michigan and her colleagues decided to try crustaxa, a drug that slows down the immune system, in patients with severe arthritis.
The limited-scale study involved an average of 32 volunteers aged 55 years with severe arthritis.
The report, published online in the latest issue of the online research journal Arthritis and Rheumatology, states that the 24-week study looked at these patients in a specific setting that limited the response of the cortex and the immune system. Medication ‘MMF’ was given.
At the end of the study, 68% of patients not only had significantly lower uric acid levels in their blood, but also significantly reduced the severity of arthritis.
Dr. Pooja says the search for a new drug is a long and time consuming affair that takes ten to twenty years.
In such a case, the strategy of using different pre-approved drugs together can also give better results in less time and in less time.
